Anti-WARS1 MAb therapy, a novel pharmacological intervention, did not directly alter the bacterial load (Fig. 7J); however, it is thought to have preserved disease tolerance via its ability to inhibit the expression of multiple cytokines and chemokines at the infection site, thereby minimizing parenchymal cell damage (Chen et al, 2018). This evidence concerns the gene WARS1 and infection.